Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

azercabtagene zapreleucel

A preparation of allogeneic, off-the-shelf, T-lymphocytes that have been genetically modified using a proprietary synthetic nuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 (cluster of differentiation 19) with potential immunostimulating and antineoplastic activities. Upon administration, azercabtagene zapreleucel specifically recognize and kill CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B-cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic anti-CD19-CAR T lymphocytes PBCAR0191
allogeneic anti-CD19-CAR T-cells PBCAR0191
allogeneic anti-CD19-CAR T-lymphocytes PBCAR0191
anti-CD19-CAR allogeneic T cells PBCAR0191
anti-CD19-CAR allogeneic T-cells PBCAR0191
Code name:PBCAR0191
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search